Main research directions:
1. Research on the molecular mechanisms of inflammation, vascular diseases and tumor neovascularization
2. New targets for major diseases based on vascular biology New drug screening
Academic positions:
1. Tenured professor in the Department of Biology and Materials Science, University of Michigan Medical School
2. Vascular biology research at Guangdong Pharmaceutical College Distinguished Professor
In July 2010, Professor Geng Jianguo’s patent and technology for the invention of this protein anti-tumor drug was licensed to Sanofi-Ann, the world’s third largest pharmaceutical company headquartered in Paris, France. Wante Company implemented the production, and the contract value was more than 60 million US dollars plus a 3% sales commission.
Research topics:
1. Research on the signal transduction mechanism of cell-cell interaction during inflammation and its application (Project No.: 2010CB529700), 2010-2014, National Ministry of Science and Technology "973" project, chief scientist, 3 million yuan
2. Modulation of leukocyte adhesion by P-selectin/PSGL-1 signaling, National Institutes of Health, 2007-2012, project leader, 13 million yuan Yuan
3. Preclinical research on Robo1-Fc recombinant protein in the treatment of tumor growth and metastasis (Project No.: 2009ZX09103), National Science and Technology Major Project, 2009-2010, Project Leader, 3 million yuan
p>
The current total available funds: 19 million yuan.